Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-03-15
2010-12-07
Whiteman, Brian (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500
Reexamination Certificate
active
07846908
ABSTRACT:
The present invention concerns methods of treatment using transforming growth factor beta (TGF-beta) modulators. More specifically, the invention concerns methods of treating disorders associated with undesirable TGF-beta signaling, by administering short interfering RNA which down-regulate the expression of TGF-beta, and agents useful therein.
REFERENCES:
patent: 5595760 (1997-01-01), Cherif-Cheikh
patent: 5672659 (1997-09-01), Shalaby et al.
patent: 5756353 (1998-05-01), Debs
patent: 5858784 (1999-01-01), Debs et al.
patent: 5902880 (1999-05-01), Thompson
patent: 6071497 (2000-06-01), Steiner et al.
patent: 6146886 (2000-11-01), Thompson
patent: 6294153 (2001-09-01), Modi
patent: 6344194 (2002-02-01), Sene et al.
patent: 6395713 (2002-05-01), Beigelman et al.
patent: 2005/0107325 (2005-05-01), Manoharan et al.
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: WO 93/23569 (1993-11-01), None
patent: WO 94/02595 (1994-02-01), None
patent: WO 96/10390 (1996-04-01), None
patent: WO 96/10391 (1996-04-01), None
patent: WO 96/10392 (1996-04-01), None
patent: WO 98/10796 (1998-03-01), None
patent: WO 98/31346 (1998-07-01), None
patent: WO 00/27359 (2000-05-01), None
patent: WO 00/53722 (2000-09-01), None
patent: WO 00/66206 (2000-11-01), None
patent: WO 01/54664 (2001-08-01), None
patent: WO 01/60420 (2001-08-01), None
patent: WO 02/053190 (2002-07-01), None
patent: WO 02/060412 (2002-08-01), None
patent: WO 02/066078 (2002-08-01), None
patent: WO 2004/064737 (2004-08-01), None
patent: WO 2004/080406 (2004-09-01), None
patent: WO 2004/094345 (2004-11-01), None
patent: WO 2004/094595 (2004-11-01), None
patent: WO 2005/015481 (2005-02-01), None
NM—000660.3 ((GenBank [online] Bethesda, MD USA: United States National Library of Medicine [retrieved on Jun. 13, 2008]. Retrieved from internet using <URL: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=63025221>, GenBank, Accession No. NM—000660).
Hammond et al. Nature, 2001, vol. 2, pp. 110-119.
Promega, retrieved from internet using <URL: http://www.promega.com/siRNADesigner/>, retrieved on Jun. 13, 2008, available 2004 to the public [online]), including search results for GenBank NM—000660 and revision history.
Aldrian-Herrada et al., “A Peptide Nucleic Acid (PNA) is More Raplidly Internalized in Cultured Neurons When Coupled to aRetro-InversoDelivery Peptide. The Antisense Activity Depresses the Target mRNA and Protein in Magnocellular Oxytocin Neurons,”Nucleic Acids Research26(11): 4910-4916 (1998).
Beaucage, S. and Iyer, R., “Advances in the Syntheseis of Oligonucleotides by the Phosphoramidite Approach,”Tetrahedron, 48(12): 2223-2311 (1992).
Boado, R., “Antisense Drug Delivery Through the Blood-Brain Barrier,”Advanced Drug Delivery Reviews15:73-107 (1995).
Boado et al., “Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS,”Journal of Pharmaceutical Sciences, 87(11): 1308-1315 (1998).
Chen et al., “Multitarget-Ribozyme Directed to Cleave at Up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication—Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates,”Nucleic Acids Research20(17): 4581-4589 (1992).
Chowrira et al., “In Vitro and In Vivo Comparison of Hammerhead, Hairpin and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes,”The Journal of Biological Chemistry269(41): 25858-25864 (1994).
Couture et al., “Anti-Gene Therapy: The Use of Ribozymes to Inhibit Gene Function,”TIG12(12): 510-515 (1996).
Dropulic et al., “Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type 1 Expression,”Journal of Virology, 66(3): 1432-1441 (1992).
Elbashir et al., “RNA Interference is Mediated by 21- and 22-Nucleotide RNAs,”Genes&Development, 15:188-200 (2001).
Fire et al., “Potent and Specific Genetic Interference by Double-Stranded RNA inCaenorhabditis elegans,” Nature391: 806-811 (1998).
Gonzalez et al., “New Class of Polymers for the Delivery of Macromolecular Therpeutics,”Bioconjugate Chem. 10: 1068-1074 (1999).
Good et al., “Expression of Small, Therapeutic RNAs in Human Cell Nuclei,”Gene Therapy4:45-54 (1997).
Izant et al., “Constitutive and Conditional Suppression of Exogenous and Endogenous Genes by Anti-Sense RNA,”Science, 229: 345-352 (1985).
Jolliet-Riant et al., “Drug Transfer Across the Blood-Brain Barrier and Improvement of Brain Delivery,”Fundam. Clin. Pharmacol. 13: 16-26 (1999).
Kashani-Sabet et al., “Reversal of the Malignant Phenotype by an Anti-rasRibozyme,”Antisense Research and Development, 2: 3-15 (1992).
Lasic et al., “Liposomes Revisited,”Science, 267: 1275-1276 (1995).
Lasic et al., “The ‘Stealth’ Liposome: A Prototypical Biomaterial,”Chemical Reviews95(8):2601-2628 (1995).
Liu et al., “Cationic Liposome-Mediated Intravenous Gene Delivery,”The Journal of Biomedical Chemistry, 270(42): 24864-24870 (1995).
McGarry et al., “Inhibition of Heat Shock Protein Synthesis by Heat-Inducible Antisense RNA,”Proc. Natl. Acad. Sci. USA83:399-403 (1986).
Nykanen et al., “ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway,”Cell107: 309-321 (2001).
Ohkawa et al., “Activities of HIV-RNA Targeted Ribozymes Transcribed from a ‘Shot-Gun’ Type Ribozyme-Trimming Plasmid,” .,Nucleic Acids Symp. Ser. 27:15-16, (1992).
Ojwang et al., “Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme,”Proc. Natl. Acad. Sci. USA89: 10802-10806 (1992).
Oku et al., “Real-Time Analysis of Liposomal Trafficking in Tumor-Bearing Mice by Use of Positron Emission Tomography,”Biochimica et Biophysica Acta, 1238:86-90 (1995).
Pardridge et al., “Vecotr-Mediated Delivery of a Polyamide (“Peptide”) Nucleic Acid Analogue Through the Blood-Brain Barrier in vivo,”PNAS92: 5592-5596 (1995).
Sandrasagra et al., “Discovery and Development of Respirable Antisense Therapeutics for Asthma,”Antisense&Nucleic Acid Drug Development12: 177-181 (2002).
Sandrasagra et al., “RASONs: A Novel Antisense Oligonucleotide Therapeutic Approach for Asthma,”Expert Opin. Biol. Ther. 1(6): 979-983 (2001).
Sarver et al., “Ribozymes as Potential Ant-HIV-1 Therapeutic Agents,”Science, 247: 1222-1225 (1990).
Scanlon et al., “Ribozyme-Mediated Cleavage of C-FOS mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein,”Proc. Natl. Acad. Sci. USA88:10591-10595 (1991).
Taira et al., “Construction of a Novel RNA-Transcript-Trimming Plasmid Which Can be Used Both in vitro in Place of Run-Off and (G)-Free Transcriptions and in vivo as Multi-Sequences Transcription Vectors,”Nucleic Acids Research19: 5125-5130 (1991).
Templin et al., “Pharmacokinetic and Toxicity Profile of a Phosphorothioate Oligonucleotide Following Inhalation Delivery to Lung in Mice,”Antisense&Nucleic Acid Drug Development, 10:359-368 (2000).
Thompson et al., “Improved Accumulation and Activity of Ribozymes Expressed from tRNA-Based RNA Polymerase III Promoter,”Nucleic Acids Research, 23(12): 2259-2268 (1995).
Tyler et al., “Peptide Nucleic Acids Targeted to the Neurotensin Receptor and Administered I.P. Cross the Blood-Brain Barrier and Specifically Reduce Gene Expression,”PNAS96: 7053-7058 (1999).
Tyler et al., “Specific Gene Blockade Shows that Peptide Nucleic Acids Readily Enter Neuronal Cells in vivo,”FEBS Letters421: 280-284 (1998).
Ventura et al., “Activation of HIV-Specific Ribozyme Activity by Self-Cleavage,”Nucleic Acids Research21(14): 3249-3255 (1993).
Weerasinghe et al., “Resistance to Human Immunodeficiency
Constien Rainer
Tan Pamela
Vornlocher Hans-Peter
Alnylam Pharmaceuticals, Inc.
Fenwick & West LLP
Whiteman Brian
LandOfFree
RNAi modulation of TGF-beta and therapeutic uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNAi modulation of TGF-beta and therapeutic uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNAi modulation of TGF-beta and therapeutic uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4232276